We can’t always win: LAVA-1207 Development Discontinued, Not Related to Safety Issues
/in Clinical Trial, Metastatic, Phase 1/by MaxUpdate on CLS-1025: Precision T Cell Engager Phase 1 Study Expected in Early 2025
/in Clinical Trial, Metastatic, Phase 1/by MaxVIR-5500: A Promising T-Cell Engager for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1b Promising Results: ORIC-944, a PRC2 Inhibitor for Advanced Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxResults from Phase 3 Trial of CAN-2409: a Promising Immunotherapy for Prostate Cancer
/in Clinical Trial, Localized/by MaxPhase 1 Trial of a Polynucleotide Kinase/Phosphatase (PNKP) Inhibitor
/in Clinical Trial, Not PCa related/by MaxPhase 1 Clinical Trial for ADRX-0405 in Advanced Solid Tumors Including Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy
Latest Posts
- B7‑H3 Expression Shapes Prognosis Differently Across Prostate Cancer Stages April 24, 2026
- DNA Smart Drugs: Precision Cancer Treatment With a Double Lock April 22, 2026
- Double-Masked PSMA-TCE JANX014 Enters Phase 1 for mCRPC April 21, 2026
- Phase 1/2 RAISIC‑1 Trial: PTT‑4256 in Advanced Solid Tumors April 20, 2026